Cosmo and Glenmark receives market authorization of Winlevi in Europe
Winlevi is authorized in EU for the treatment of acne vulgaris
Winlevi is authorized in EU for the treatment of acne vulgaris
The company says the innovation delivers stronger moisture protection for highly sensitive drug molecules
The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
The drug is being tested for combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
These initiatives will harness top scientific talent and advanced AI technologies to develop new ways to slow the rise of drug-resistant infections
Subscribe To Our Newsletter & Stay Updated